Altre lingue Percheron Therapeutics Limited Deutsche Boerse AG

Azioni

AWY0

AU0000317281

Mercato chiuso - Deutsche Boerse AG Altri mercati azionari 08:05:20 25/06/2024			Variaz. 5gg	Var. 1 gen.
0,0456 ^EUR	+0,66%		-2,15%	+48,05%

29/05	Percheron Therapeutics completa l'arruolamento per lo studio di fase due sulla distrofia muscolare; le azioni salgono del 3%.	MT
28/02	Percheron Therapeutics Limited riporta i risultati degli utili per il semestre conclusosi il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Percheron Therapeutics Appoints CFO	17/06
Percheron Therapeutics Names Chief Medical Advisor	03/06
Percheron Therapeutics Completes Enrollment for Phase Two Muscular Dystrophy Trial; Shares Rise 3%	29/05
Percheron Therapeutics Secures US Patent for Muscular Dystrophy Medicinal Candidate	20/05
WHO Selects International Nonproprietary Name for Percheron Therapeutics' Drug Candidate ATL1102	06/05
Percheron Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	28/02
Dimerix Appoints Nonexecutive Chair	20/11
Antisense Therapeutics Limited has Changed its Name to Percheron Therapeutics Limited	15/11
Antisense Therapeutics Launches Share Sale Facility for Unmarketable Parcels	09/10/23
Antisense Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	25/08/23
Antisense Therapeutics' Share Purchase Plan Raises AU$3.3 Million	21/08/23
Antisense Therapeutics Appoints CEO/Managing Director	07/08/23
Antisense Therapeutics Limited Announces Commencement of James Garner as Chief Executive Officer, Effective 7 August 2023	07/08/23
Antisense Therapeutics Limited Announces Management Changes	07/08/23
Antisense Therapeutics to Launch Share Purchase Plan; Shares Plunge 8%	20/07/23
Antisense Therapeutics Limited Receives MHRA Approval for ATL1102 Phase IIb DMD Clinical Trial in UK	27/06/23
Antisense Therapeutics Doses First Patient in Duchenne Muscular Dystrophy Drug Trial; Shares Jump 11%	08/06/23
Antisense Therapeutics Appoints CEO/Managing Director	08/05/23
Antisense Therapeutics Limited Announces the Appointment of James Garner as Chief Executive Officer, Effective 07 August 2023	08/05/23
Antisense Therapeutics Limited Appoints James Garner as Managing Director and to Join the Board as a Non-Executive Director	08/05/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Percheron Therapeutics Limited Deutsche Boerse AG

Azioni

AWY0

AU0000317281

Altre lingue

Filtri